# A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

> **NCT05723549** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP1803-3
- **DRUG:** RLD2002
- **DRUG:** HCP1904-1

## Key facts

- **NCT ID:** NCT05723549
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-02
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-03-20
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05723549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05723549, "A Study to Evaluate the PK, Safety and Tolerability of HCP1803.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05723549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*